Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

37.81USD
19 Oct 2018
Change (% chg)

-- (--)
Prev Close
$37.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
324,483
52-wk High
$68.05
52-wk Low
$30.00

Latest Key Developments (Source: Significant Developments)

Global Blood Therapeutics Reports Q2 Loss Per Share Of $0.78
Friday, 3 Aug 2018 

Aug 2 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND PROVIDES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.78.Q2 EARNINGS PER SHARE VIEW $-0.88 -- THOMSON REUTERS I/B/E/S.  Full Article

GBT Announces Positive Top-Line Data From Part A Of The Phase 3 Hope Study Of Voxelotor In Sickle Cell Disease
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES POSITIVE TOP-LINE DATA FROM PART A OF THE PHASE 3 HOPE STUDY OF VOXELOTOR IN SICKLE CELL DISEASE.GLOBAL BLOOD THERAPEUTICS INC - PHASE 3 HOPE STUDY PRIMARY ENDPOINT ACHIEVED.GLOBAL BLOOD THERAPEUTICS - MET FDA ON JUNE 25 AND IS IN DISCUSSIONS ON POTENTIAL ACCELERATED APPROVAL BASED ON HEMOLYTIC ANEMIA EFFICACY ASSESSED BY PRIMARY ENDPOINT.GLOBAL BLOOD THERAPEUTICS INC - VOXELOTOR WAS GENERALLY SAFE AND WELL TOLERATED WITH SIMILAR SAFETY PROFILES BETWEEN TWO DOSES.GLOBAL BLOOD THERAPEUTICS INC - "BASED UPON VOXELOTOR'S ROBUST IMPACT ON HEMOLYTIC ANEMIA, WE BELIEVE IT MEETS STANDARD FOR ACCELERATED APPROVAL".GLOBAL BLOOD THERAPEUTICS INC - APPROVAL BASED ON HEMOLYTIC ANEMIA EFFICACY AS ASSESSED BY PRIMARY ENDPOINT.  Full Article

GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Global Blood Therapeutics Inc ::GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD).  Full Article

Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING.  Full Article

Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - ANNOUNCED AN AGREEMENT TO SELL $100.0 MILLION IN SHARES OF ITS COMMON STOCK.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE.  Full Article

Global Blood Therapeutics posts Q3 loss per share $0.66
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Global Blood Therapeutics Inc :Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results.Q3 loss per share $0.66.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Global Blood Therapeutics - continue to expect cash,cash equivalents,marketable securities to be enough to take co to top-line data in hope study​.Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016​.  Full Article

Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Global Blood Therapeutics Inc ::Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440.Global Blood Therapeutics Inc - ‍world Health Organization has approved "voxelotor" as international nonproprietary name for gbt440​.  Full Article

Global Blood Therapeutics announces discontinuation of IPF program
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Global Blood Therapeutics Inc :Global Blood Therapeutics announces discontinuation of Idiopathic Pulmonary Fibrosis (IPF) program​.Says discontinuation of its GBT440 program for treatment of idiopathic pulmonary fibrosis​.Says ‍decision to discontinue is based on results from 3 proof-of-concept studies including phase 1 study in healthy volunteers.Says ‍decision to discontinue is also based on two phase 2A studies in patients with ipf called GBT440-006 and Zephyr​.Says data from proof-of-concept studies did not demonstrate sufficient overall clinical benefit to justify continuing IPF program.Says ‍remain on track to announce top-line clinical trial results from phase 3 Hope study in H1 2019 ​.Says ‍GBT440 was generally well tolerated across all three studies​.  Full Article

GBT's drug meets trial goal, investors skeptical of speedy approval

Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.